Comprehensive Geriatric Assessment (CGA) of elderly lung cancer patients: A single-center experience

Gironés, Regina; Torregrosa, Dolores; Maestu, Inmaculada; Gómez-Codina, José; Tenias, Jose María; Costa, R. Rosell

doi:10.1016/j.jgo.2011.12.005

Cited by 43 publications

(40 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Meanwhile, we noticed that few data available when searching about CGA or PACE especially on elderly NSCLC surgical candidates. 19) Different instruments have been valid to encourage oncologists for screening older cancer patients for further a CGA. 20) So we think it is urgent to emphasize the perioperative comprehensive assessment of aging but not only fulfill the common criteria of lobectomy.…”

Section: Discussionmentioning

confidence: 99%

Outcome of VATS Lobectomy for Elderly Non-Small Cell Lung Cancer: A Propensity Score-Matched Study

Sui

Zhao

Wang

et al. 2015

ATCS

View full text Add to dashboard Cite

Purpose: To analyze the short-term and long-term outcome of video-assisted thoracic surgery (VATS) lobectomy for elderly patients with non-small cell lung cancer. Methods: 105 patients aged ≥75 years with resected non-small cell lung cancer were matched with 105 younger patients by propensity score. Survival rates were calculated by the Kaplan-Meier method. The cumulative incidence functions of conditional survival rate according to the age of the patients were calculated by competing risk analysis. Results: patients ≥75 years was associated with higher postoperative complication rate (p <0.001), but similar perioperative death rate (p = 0.006). Patients ≥75 years were less likely to receive adjuvant chemotherapy (p <0.001). The 5-year overall survival rates were 54.6% for patients ≥75 years and 74.1% for patients <75 years (p = 0.001). No difference was seen in disease-free survival rate (59.5% vs. 71.9% respectively = 0.117). The cumulative incidence functions of 5-year cancer-specific death were similar between the two groups (28.7% vs. 24.6% respectively, p = 0.106). The cumulative incidence functions of 5-year non-cancer-specific death was significantly higher in the elderly group (18.7% vs. 1.0%, p <0.001). Conclusions: VATS lobectomy for non-small-cell lung cancer in patients ≥75 years were feasible with increased morbidity but similar mortality. The resected elderly patients were more frequently associated with non-cancer-specific death.

show abstract

Section: Discussionmentioning

confidence: 99%

Outcome of VATS Lobectomy for Elderly Non-Small Cell Lung Cancer: A Propensity Score-Matched Study

Sui

Zhao

Wang

et al. 2015

ATCS

View full text Add to dashboard Cite

show abstract

“…3,15,19 If no GA inclusion criteria are predefined, Lazarovici et al 20 found that weight loss is the main reason for oncologists to refer older patients with cancer for a GA. Concerning eligibility criteria, more than half of the respondents stated that GA should ideally be applied in all patients, aged 70 years or older, in whom a treatment decision (i.e.…”

Section: Discussionmentioning

confidence: 99%

Multicenter implementation of geriatric assessment in Belgian patients with cancer: A survey on treating physicians' general experiences and expectations

Kenis

Heeren

Bron

et al. 2014

Journal of Geriatric Oncology

View full text Add to dashboard Cite

“…9,22,26 Other important factors such as geriatric assessment and frailty scoring were not included in this study as it was limited to Medicare data. 36 Despite these limitations, our study included a large, diverse sample of men with Medicare.…”

Section: Discussionmentioning

confidence: 99%

A new approach to understanding racial disparities in prostate cancer treatment

Presley

Raldow

Cramer

et al. 2013

Journal of Geriatric Oncology

View full text Add to dashboard Cite

Objective Previous studies addressing racial disparities in treatment for early-stage prostate cancer have focused on the etiology of undertreatment of black men. Our objective was to determine whether racial disparities are attributable to undertreatment, overtreatment, or both. Methods Using the SEER-Medicare dataset, we identified men 67–84 years-old diagnosed with localized prostate cancer from 1998 to 2007. We stratified men into clinical benefit groups using tumor aggressiveness and life expectancy. Low-benefit was defined as low-risk tumors and life expectancy <10 years; high-benefit as moderate-risk tumors and life expectancy ≥10 years; all others were intermediate-benefit. Logistic regression modeled the association between race and treatment (radical prostatectomy or radiotherapy) across benefit groups. Results Of 68,817 men (9.8% black and 90.2% white), 56.2% of black and 66.3% of white men received treatment (adjusted odds ratio (OR)=0.65; 95% CI, 0.62–0.69). The percent of low-, intermediate-, and high-benefit men who received treatment was 56.7%, 68.4%, and 79.6%, respectively (P=<0.001). In the low-benefit group, 51.9% of black vs. 57.2% of white patients received treatment (OR=0.74; 95% CI, 0.67–0.81) compared to 57.2% vs. 69.6% in the intermediate-benefit group (OR=0.64; 95% CI, 0.59–0.70). Racial disparity was largest in the high-benefit group (64.2% of black vs. 81.4% of white patients received treatment; OR=0.57; 95% CI, 0.48–0.68). The interaction between race and clinical benefit was significant (P<0.001). Conclusion Racial disparities were largest among men most likely to benefit from treatment. However, a substantial proportion of both black and white men with a low clinical benefit received treatment, indicating a high level of overtreatment.

show abstract

Comprehensive Geriatric Assessment (CGA) of elderly lung cancer patients: A single-center experience

Cited by 43 publications

References 25 publications

Outcome of VATS Lobectomy for Elderly Non-Small Cell Lung Cancer: A Propensity Score-Matched Study

Outcome of VATS Lobectomy for Elderly Non-Small Cell Lung Cancer: A Propensity Score-Matched Study

Multicenter implementation of geriatric assessment in Belgian patients with cancer: A survey on treating physicians' general experiences and expectations

A new approach to understanding racial disparities in prostate cancer treatment

Contact Info

Product

Resources

About